...
首页> 外文期刊>Frontiers in Pharmacology >The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis
【24h】

The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis

机译:PD-L1表达在结直肠癌中的预后和临床病理作用:系统评价和Meta分析。

获取原文
           

摘要

Background: Studies evaluating the prognostic significance of programmed death-ligand 1 (PD-L1) expression in colorectal cancer (CRC) are limited and remain controversial. This meta-analysis was conducted in order to evaluate the clinicopathological and prognostic significance of PD-L1 expression in CRC patients. Methods: A comprehensive search was performed against the Medline/PubMed, Embase, Cochrane Library, Web of Science (WoS) and Scopus databases. Data were extracted with name of the first author, year of publication, country of origin, tumor type, number of cases, staining method, cut-off values, PD-L1 positive expression, clinicopathological parameters, outcome, and quality assessment score, and statistical analysis was conducted using Review Manager Version 5.3 (Revman the Cochrane Collaboration; Oxford, England) and STATA version 14 (Stata Corporation; College Station, TX, USA). Results: Ten studies were included in this meta-analysis, in which the pooled hazard ratio (HR) showed that PD-L1 expression in tumor cells was significantly associated with a poor overall survival (HR = 1.50, 95% CI 1.05–2.13, P = 0.03). The pooled HR for disease-free survival (DFS) indicated that PD-L1 expression was significantly associated with shorter DFS (HR = 2.57, 95% CI 1.40–4.75, P = 0.002). The pooled odds ratios (ORs) showed that PD-L1 expression was associated with poor differentiation (OR = 3.47, 95% CI 1.37–8.77, P = 0.008) and right colon cancer (OR = 2.38, 95% CI 1.57–3.60, P & 0.0001). However, the expression of PD-L1 was independent of gender, age, tumor size, tumor stage, lymph node metastasis, and tumor-node metastasis stage. Conclusion: This meta-analysis indicated that a high level of PD-L1 expression might be a biomarker for a poor prognosis in CRC patients. This information may be helpful for clinicians to stratify CRC patients for anti-PD-1/PD-L1 therapy, particularly patients with microsatellite instability high (MSI-H).
机译:背景:评估程序性死亡配体1(PD-L1)在结直肠癌(CRC)中的预后意义的研究有限,并且仍存在争议。进行这项荟萃分析,以评估CRC患者PD-L1表达的临床病理和预后意义。方法:对Medline / PubMed,Embase,Cochrane图书馆,Web of Science(WoS)和Scopus数据库进行了全面搜索。提取的数据包括第一作者的姓名,发表的年份,起源的国家,肿瘤的类型,病例数,染色方法,临界值,PD-L1阳性表达,临床病理参数,结局和质量评估得分,以及使用Review Manager 5.3版(Revman Cochrane Collaboration;英国牛津)和STATA 14版(Stata Corporation;美国德克萨斯州大学城)进行统计分析。结果:这项荟萃分析包括10项研究,其中合并危险比(HR)显示肿瘤细胞中PD-L1表达与总体存活率低显着相关(HR = 1.50,95%CI 1.05-2.13, P = 0.03)。无病生存期(HR)汇总的HR数据表明PD-L1表达与较短的DFS显着相关(HR = 2.57,95%CI 1.40–4.75,P = 0.002)。汇总的优势比(OR)显示PD-L1表达与分化不良(OR = 3.47,95%CI 1.37–8.77,P = 0.008)和右结肠癌(OR = 2.38,95%CI 1.57–3.60, P <0.0001)。然而,PD-L1的表达与性别,年龄,肿瘤大小,肿瘤分期,淋巴结转移和肿瘤淋巴结转移阶段无关。结论:这项荟萃分析表明高水平的PD-L1表达可能是CRC患者预后不良的生物标志。该信息可能有助于临床医生对CRC患者进行抗PD-1 / PD-L1治疗的分层,特别是微卫星不稳定性高(MSI-H)的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号